Facing treatment of non-urothelial bladder cancers in the immunotherapy era.
Bladder adenocarcinoma
Checkpoint inhibitors
Immunotherapy
Non-urothelial bladder cancer
Squamous cell bladder cancer
Variant urothelial cancer
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
29
12
2019
revised:
15
06
2020
accepted:
15
06
2020
pubmed:
6
7
2020
medline:
25
9
2020
entrez:
5
7
2020
Statut:
ppublish
Résumé
Non-urothelial Bladder Cancer (BC) and variants of urothelial carcinoma account for up to 25 % of all BCs. Given their heterogeneity, these entities are not well represented in clinical trials and treatment remains challenging. Checkpoint inhibitor therapy has shown a role in the treatment of urothelial BC. By contrast, robust evidence regarding its use in other histological types is lacking. We aimed to provide a comprehensive update of non-urothelial and variant urothelial BC, exploring the evidence for immune checkpoint inhibitor therapy. A detailed analysis of the literature was conducted regarding epidemiology, aetiology, diagnosis, prognosis, treatment and outcomes of these patients in the immunotherapy era. A growing body of evidence suggests that immune checkpoint inhibition might have a role to play in non-urothelial BC, similarly to what happened with urothelial carcinomas.
Identifiants
pubmed: 32622321
pii: S1040-8428(20)30172-4
doi: 10.1016/j.critrevonc.2020.103034
pii:
doi:
Substances chimiques
Immunologic Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103034Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.